| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/26/2022 | 97.24% | RBC Capital | $2 → $1 | Maintains | Sector Perform |
| 08/16/2022 | 146.55% | Credit Suisse | $1.5 → $1.25 | Maintains | Underperform |
| 03/16/2022 | 245.17% | Evercore ISI Group | $4.5 → $1.75 | Maintains | In-Line |
| 03/16/2022 | 97.24% | Morgan Stanley | $3 → $1 | Maintains | Equal-Weight |
| 03/03/2022 | 294.48% | RBC Capital | $10 → $2 | Downgrades | Outperform → Sector Perform |
| 03/02/2022 | 294.48% | Truist Securities | → $2 | Downgrades | Buy → Hold |
| 01/07/2022 | 491.72% | Credit Suisse | $6 → $3 | Downgrades | Neutral → Underperform |
| 01/05/2022 | 590.34% | B of A Securities | $7.5 → $3.5 | Downgrades | Buy → Underperform |
| 11/15/2021 | 1083.43% | Credit Suisse | $7 → $6 | Maintains | Neutral |
| 11/11/2021 | 984.81% | Morgan Stanley | $13 → $5.5 | Maintains | Equal-Weight |
| 11/10/2021 | 1872.39% | RBC Capital | $17 → $10 | Maintains | Outperform |
| 11/10/2021 | 886.19% | Barclays | $10 → $5 | Downgrades | Overweight → Equal-Weight |
| 11/09/2021 | 886.19% | Barclays | → $5 | Downgrades | Overweight → Equal-Weight |
| 08/13/2021 | 1872.39% | Barclays | $18 → $10 | Maintains | Overweight |
| 08/12/2021 | 2464.1% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 08/12/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/12/2021 | 1872.39% | Credit Suisse | $18 → $10 | Downgrades | Outperform → Neutral |
| 08/12/2021 | 1675.15% | Evercore ISI Group | → $9 | Downgrades | Outperform → In-Line |
| 05/17/2021 | 2661.34% | Raymond James | $15 → $14 | Maintains | Outperform |
| 05/17/2021 | 3450.3% | Credit Suisse | $19 → $18 | Maintains | Outperform |
| 05/14/2021 | 2661.34% | Morgan Stanley | $13 → $14 | Maintains | Equal-Weight |
| 03/15/2021 | 2858.58% | Raymond James | $18 → $15 | Maintains | Outperform |
| 03/10/2021 | 2464.1% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 03/09/2021 | 3647.53% | Credit Suisse | $21 → $19 | Maintains | Outperform |
| 11/16/2020 | 4042.01% | Credit Suisse | $25 → $21 | Maintains | Outperform |
| 11/12/2020 | 2661.34% | Morgan Stanley | $18 → $14 | Maintains | Equal-Weight |
| 10/02/2020 | 3450.3% | Raymond James | → $18 | Initiates Coverage On | → Outperform |
| 08/20/2020 | 3450.3% | Morgan Stanley | $17 → $18 | Maintains | Equal-Weight |
| 08/10/2020 | 5225.44% | Evercore ISI Group | → $27 | Initiates Coverage On | → Outperform |
| 08/10/2020 | 4830.97% | Credit Suisse | → $25 | Initiates Coverage On | → Outperform |
| 08/10/2020 | 3253.06% | Morgan Stanley | → $17 | Initiates Coverage On | → Equal-Weight |
| 08/10/2020 | 5028.21% | Truist Securities | → $26 | Initiates Coverage On | → Buy |
| 08/10/2020 | 5028.21% | Cantor Fitzgerald | → $26 | Initiates Coverage On | → Overweight |
| 08/10/2020 | 4239.25% | Barclays | → $22 | Initiates Coverage On | → Overweight |
| 08/10/2020 | 4042.01% | Goldman Sachs | → $21 | Initiates Coverage On | → Buy |
| 08/10/2020 | 4239.25% | B of A Securities | → $22 | Initiates Coverage On | → Buy |
GoHealth Questions & Answers
The latest price target for GoHealth (NASDAQ: GOCO) was reported by RBC Capital on August 26, 2022. The analyst firm set a price target for $1.00 expecting GOCO to rise to within 12 months (a possible 97.24% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for GoHealth (NASDAQ: GOCO) was provided by RBC Capital, and GoHealth maintained their sector perform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GoHealth, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GoHealth was filed on August 26, 2022 so you should expect the next rating to be made available sometime around August 26, 2023.
While ratings are subjective and will change, the latest GoHealth (GOCO) rating was a maintained with a price target of $2.00 to $1.00. The current price GoHealth (GOCO) is trading at is $0.51, which is out of the analyst's predicted range.